Alliance Pharma (LSE:APH) EV-to-EBIT : 123.95 (As of Apr. 29, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alliance Pharma's Enterprise Value is £287.2 Mil. Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil. Therefore, Alliance Pharma's EV-to-EBIT for today is 123.95.

The historical rank and industry rank for Alliance Pharma's EV-to-EBIT or its related term are showing as below:

LSE:APH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.27 Med: 13.93 Max: 123.95
Current: 123.95

During the past 13 years, the highest EV-to-EBIT of Alliance Pharma was 123.95. The lowest was 8.27. And the median was 13.93.

LSE:APH's EV-to-EBIT is ranked worse than
96.11% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.21 vs LSE:APH: 123.95

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alliance Pharma's Enterprise Value for the quarter that ended in Jun. 2023 was £367.6 Mil. Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil. Alliance Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 0.63%.

Alliance Pharma EV-to-EBIT Historical Data

The historical data trend for Alliance Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma EV-to-EBIT Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

16.85

14.77

38.43

31.92

39.23

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial															-	31.92	-	39.23	-

Competitive Comparison of Alliance Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alliance Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's EV-to-EBIT falls into.

Alliance Pharma EV-to-EBIT Calculation

Alliance Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	287.184	/	2.317
	=	123.95

Alliance Pharma's current Enterprise Value is £287.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil.

Alliance Pharma (LSE:APH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alliance Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	2.317	/	367.578775
	=	0.63 %

Alliance Pharma's Enterprise Value for the quarter that ended in Jun. 2023 was £367.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £2.3 Mil.

Alliance Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).